107 related articles for article (PubMed ID: 24368529)
61. A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688.
Kostakoglu L; Duan F; Idowu MO; Jolles PR; Bear HD; Muzi M; Cormack J; Muzi JP; Pryma DA; Specht JM; Hovanessian-Larsen L; Miliziano J; Mallett S; Shields AF; Mankoff DA;
J Nucl Med; 2015 Nov; 56(11):1681-9. PubMed ID: 26359256
[TBL] [Abstract][Full Text] [Related]
62. Stratification of 18F-labeled PET imaging agents for the assessment of antiangiogenic therapy responses in tumors.
Goggi JL; Bejot R; Moonshi SS; Bhakoo KK
J Nucl Med; 2013 Sep; 54(9):1630-6. PubMed ID: 23907757
[TBL] [Abstract][Full Text] [Related]
63. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer.
van Westreenen HL; Cobben DC; Jager PL; van Dullemen HM; Wesseling J; Elsinga PH; Plukker JT
J Nucl Med; 2005 Mar; 46(3):400-4. PubMed ID: 15750150
[TBL] [Abstract][Full Text] [Related]
64. The Value of 5-Aminolevulinic Acid in Low-grade Gliomas and High-grade Gliomas Lacking Glioblastoma Imaging Features: An Analysis Based on Fluorescence, Magnetic Resonance Imaging, 18F-Fluoroethyl Tyrosine Positron Emission Tomography, and Tumor Molecular Factors.
Jaber M; Wölfer J; Ewelt C; Holling M; Hasselblatt M; Niederstadt T; Zoubi T; Weckesser M; Stummer W
Neurosurgery; 2016 Mar; 78(3):401-11; discussion 411. PubMed ID: 26366972
[TBL] [Abstract][Full Text] [Related]
65. Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma.
Schiepers C; Dahlbom M; Chen W; Cloughesy T; Czernin J; Phelps ME; Huang SC
J Nucl Med; 2010 May; 51(5):720-7. PubMed ID: 20395318
[TBL] [Abstract][Full Text] [Related]
66. Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme.
Lee IH; Piert M; Gomez-Hassan D; Junck L; Rogers L; Hayman J; Ten Haken RK; Lawrence TS; Cao Y; Tsien C
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):479-85. PubMed ID: 18834673
[TBL] [Abstract][Full Text] [Related]
67. Evaluation of the antitumor effects of rilotumumab by PET imaging in a U-87 MG mouse xenograft model.
Rex K; Lewis XZ; Gobalakrishnan S; Glaus C; Silva MD; Radinsky R; Burgess TL; Gambhir SS; Coxon A
Nucl Med Biol; 2013 May; 40(4):458-63. PubMed ID: 23454250
[TBL] [Abstract][Full Text] [Related]
68. Advances in PET imaging of brain tumors: a referring physician's perspective.
Petrirena GJ; Goldman S; Delattre JY
Curr Opin Oncol; 2011 Nov; 23(6):617-23. PubMed ID: 21825989
[TBL] [Abstract][Full Text] [Related]
69. Monoamine Oxidase B Binding of 18F-THK5351 to Visualize Glioblastoma and Associated Gliosis: An Autopsy-Confirmed Case.
Tago T; Toyohara J; Sengoku R; Murayama S; Ishii K
Clin Nucl Med; 2019 Jun; 44(6):507-509. PubMed ID: 30985435
[TBL] [Abstract][Full Text] [Related]
70. Role of 68Ga-Prostate-Specific Membrane Antigen PET/CT in Disease Assessment in Glioblastoma Within 48 Hours of Surgery.
Gupta M; Choudhury PS; Premsagar IC; Gairola M; Ahlawat P
Clin Nucl Med; 2020 Mar; 45(3):204-205. PubMed ID: 31977462
[TBL] [Abstract][Full Text] [Related]
71. Editorial Comment: MRI and PET for Immunotherapy Response Assessment in Glioblastoma Multiforme.
Prattipati V
AJR Am J Roentgenol; 2022 Apr; 218(4):597. PubMed ID: 34319166
[No Abstract] [Full Text] [Related]
72. Occurrence of glioblastoma multiforme in three closely related patients.
Siqueira EB; Kranzler LI; Schaffer L
Surg Neurol; 1985 Oct; 24(4):387-91. PubMed ID: 2994246
[TBL] [Abstract][Full Text] [Related]
73. Congenital Glioblastoma: Lessons Learned from a Rare Case with Unusual Presentation.
Nsir AB; Darmoul M; Hadhri R; Hattab N
Turk Neurosurg; 2017; 27(3):464-467. PubMed ID: 27438622
[TBL] [Abstract][Full Text] [Related]
74. Proton beam radiation-induced glioblastoma multiforme.
Schutt CA; Sargent E; Kabolizadeh P; Grills IS; Jacob J
J Neurosurg Sci; 2019 Oct; 63(5):609-610. PubMed ID: 29582971
[No Abstract] [Full Text] [Related]
75. Visual field changes as an early indicator of glioblastoma multiforme progression: two cases of functional vision changes before MRI detection.
Xie K; Liu CY; Hasso AN; Crow RW
Clin Ophthalmol; 2015; 9():1041-7. PubMed ID: 26089636
[TBL] [Abstract][Full Text] [Related]
76. Molecular imaging with FLT: a case of Cassandra's curse?
Hicks RJ
Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2687-2689. PubMed ID: 34081154
[No Abstract] [Full Text] [Related]
77. Subependymal Spread of Glioblastoma Multiforme in Positron Emission Tomography/Computed Tomography.
Chiaravalloti A; Sannino OS
Indian J Nucl Med; 2017; 32(1):81-82. PubMed ID: 28243000
[No Abstract] [Full Text] [Related]
78. Imaging in neuro-oncology.
Nandu H; Wen PY; Huang RY
Ther Adv Neurol Disord; 2018; 11():1756286418759865. PubMed ID: 29511385
[TBL] [Abstract][Full Text] [Related]
79. Macrophages as a potential tumor-microenvironment target for noninvasive imaging of early response to anticancer therapy.
Cao Q; Yan X; Chen K; Huang Q; Melancon MP; Lopez G; Cheng Z; Li C
Biomaterials; 2018 Jan; 152():63-76. PubMed ID: 29111494
[TBL] [Abstract][Full Text] [Related]
80. An Update on the Approach to the Imaging of Brain Tumors.
Mullen KM; Huang RY
Curr Neurol Neurosci Rep; 2017 Jul; 17(7):53. PubMed ID: 28516376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
